Exchange: NASDAQ·Updated 07:59 PM EDT
NTLA logo

NTLAIntellia Therapeutics Inc

$15.50
$0.25
(1.64%)
Today
Closed $15.50
$0.13
(0.84%)
After Hours
EarningsAug 6
Mkt Cap$2.13B
Vol3.62M
News
all
press releases
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Key PointsIntellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
This Stock Is Up 58% This Year. Is It too Late to Buy?
Key PointsOne of Intellia Therapeutics' leading candidates recently aced a phase 3 study...
Nasdaq News: Markets
News Placeholder
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.
Zacks
News Placeholder
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
News Placeholder
Nasdaq, S&P 500 Futures Cheer Iran Breakthrough, Crude Slides: Why SPCX, NVDA, RKLB, ASTS, RCAT, NTLA Are Keeping Traders Hooked
Despite the rebound in futures, Stocktwits data showed retail sentiment has moved to ‘bearish’ on SPY and QQQ.
Stocktwits
News Placeholder
Why Is NTLA Stock Jumping 5% Premarket Today?
Intellia unveiled additional Phase 3 data for its CRISPR-based HAE treatment, Lonvo-z.
Stocktwits
News Placeholder
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.
Zacks
News Placeholder
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
Zacks
News Placeholder
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.
Zacks
<
1
2
...
>

Advertisement|Remove ads.